急诊静脉血气检查患者初始外周静脉pO2与48小时临床恶化的关联
这项单中心观察性队列研究纳入973例在急诊接受静脉血气检测的成人,103例(10.6%)48小时内出现复合结局(ICU入住、死亡、血管加压药使用或正压通气)。中位静脉pO2为33 mmHg(IQR 25-44)。调整年龄和乳酸后,静脉pO2每升高10 mmHg的aOR为1.054(95% CI 0.957-1.161;p=0.289)。年龄加乳酸模型AUROC为0.649,加入静脉pO2后为0.654(ΔAUROC 0.005;DeLong p=0.390)。
要点
- 在急诊接受静脉血气的成人中,静脉pO2调整年龄和乳酸后与48小时复合恶化结局无关联(aOR 1.054/10 mmHg;95% CI 0.957-1.161;p=0.289)。
- 本队列中48小时复合结局发生率为10.6%(103/973),复合结局包括ICU入住、死亡、血管加压药使用或正压通气。
- 加入静脉pO2后AUROC仅从0.649升至0.654(ΔAUROC 0.005;DeLong p=0.390),未显示超越年龄和乳酸的预后增益。
- 该证据不支持将静脉pO2作为急诊普通成人静脉血气患者的48小时恶化风险分层指标。
- 原文提示不能排除更小的关联或在特定疾病人群中的潜在用途,但尚需更大样本、连续入组和外部验证确认。
适用人群与场景
- 急诊单中心接受静脉血气检测的成人患者,采用前瞻性入组和指标收集、回顾性确认48小时结局的ambispective观察队列。
- 共纳入973例成人患者,原文未给出具体纳入和排除标准细节。
诊断标准与关键阈值
- 主要结局为48小时内复合结局:ICU入住、死亡、血管加压药使用或正压通气。
- 静脉pO2按连续变量建模,调整年龄和乳酸后进行多因素logistic回归分析。
- 预后区分度比较使用AUROC:年龄加乳酸模型0.649,加入静脉pO2后0.654。
处置流程与药物剂量
- 原文为预后关联研究,未提供治疗流程或药物剂量推荐。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型为ambispective观察性队列研究,单中心城市学术急诊,共973例成人;103例(10.6%)出现48小时复合结局。
- 中位外周静脉pO2为33 mmHg(IQR 25-44)。
- 主要分析:调整年龄和乳酸后,静脉pO2与48小时临床恶化无关联,aOR 1.054/10 mmHg;95% CI 0.957-1.161;p=0.289。
- 增量表现:年龄加乳酸模型AUROC 0.649,加入静脉pO2后AUROC 0.654(ΔAUROC 0.005;DeLong p=0.390)。
- 原文结论指出:不能排除更小的关联或在特定疾病人群中的潜在效用;需更大规模多中心队列采用连续入组并进行外部验证。
证据类型、等级与局限
- 证据类型为ambispective观察性队列研究。
- 局限包括:单中心、城市学术急诊、非连续入组、48小时结局回顾性确认;原文提示不能排除较小关联,需更大样本连续入组并做外部验证。
对床旁实践的改变
- 对普通急诊成人静脉血气患者,不应将外周静脉pO2常规用于48小时临床恶化的风险分层。
- 静脉pO2在调整年龄和乳酸后未显示额外预后价值,现有以年龄和乳酸为基础的判断不宜因静脉pO2数值而调整。
- 该结论不适用于原文未研究的特定疾病人群;原文提示潜在疾病特异性用途尚需前瞻性验证,不能外推。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Peripheral venous pO2 is routinely reported with venous blood gas (VBG) results despite uncertainty regarding its prognostic significance. We evaluated whether initial peripheral venous pO2 was associated with 48-h clinical deterioration and provided prognostic information beyond age and lactate.
METHODS: We conducted an ambispective observational cohort study of adults undergoing VBG testing at a single urban academic emergency department, with prospective enrollment and index-data collection and retrospective ascertainment of 48-h outcomes. The primary outcome was a composite of ICU admission, death, vasopressor use, or positive-pressure ventilation within 48 h. The primary analysis modeled venous pO2 continuously and used multivariable logistic regression adjusted for age and lactate. Incremental performance was evaluated exploratorily by comparing an age-and-lactate model with a model additionally containing venous pO2.
RESULTS: Among 973 patients, 103 (10.6%) experienced the composite outcome. Median venous pO2 was 33 mmHg (IQR 25-44). Venous pO2 was not associated with clinical deterioration after adjustment for age and lactate (adjusted odds ratio [aOR] 1.054 per 10-mmHg increase; 95% CI 0.957-1.161; p = 0.289). The AUROC was 0.649 for the age-and-lactate model and 0.654 after adding venous pO2 (ΔAUROC 0.005; DeLong p = 0.390).
CONCLUSION: In this single-center cohort of adult ED patients undergoing VBG testing, no association was observed between peripheral venous pO2 and 48-h clinical deterioration. Adding venous pO2 did not improve apparent prognostic performance beyond age and lactate. We cannot exclude smaller associations or potential utility in selected disease-specific populations. Confirmation in larger multicenter cohorts using consecutive enrollment and external validation is needed.
参考来源
- Corbo, Gruber, Acosta, et al. Association of Initial Peripheral Venous pO2 With 48-Hour Clinical Deterioration in Emergency Department Patients Undergoing Venous Blood Gas Testing. Acad Emerg Med. 2026. PMID: 42947281. doi:10.1111/acem.70429
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。